Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma Academic Article uri icon

Overview

MeSH Major

  • Carcinoma, Renal Cell
  • Kidney Neoplasms
  • Neoplasm Invasiveness
  • Salvage Therapy
  • Sirolimus

abstract

  • In patients with advanced RCC, CCI-779 showed antitumor activity and encouraging survival and was generally well tolerated over the three dose levels tested.

publication date

  • December 2004

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1200/JCO.2004.08.185

PubMed ID

  • 14990647

Additional Document Info

start page

  • 909

end page

  • 18

volume

  • 22

number

  • 5